Alecensa’s revenue trends
Roche’s (RHHBY) Alecensa generated revenues of 279.0 million Swiss francs in the first half compared to 148.0 million Swiss francs in the first half of 2017, reflecting ~91.0% YoY growth at CER.
In the United States, Europe, and Japan markets, Alecensa generated first-half revenues of 133.0 million Swiss francs, 37.0 million Swiss francs, and 86.0 million Swiss francs, respectively. In the United States market, Alecensa witnessed ~87.0% YoY growth at CER in the first half. Alecensa generated revenues of 160.0 million Swiss francs in the second quarter, reflecting ~98.0% YoY growth at CER.
In May, Roche presented follow-up data from the Phase 3 ALEX trial. Roche conducted the Phase 3 ALEX trial to evaluate the safety and efficacy of Alecensa in the first-line setting for the treatment of individuals with anaplastic lymphoma kinase (or ALK) positive metastatic non-small cell lung cancer (or NSCLC).
In the Phase 3 ALEX trial, after two years of follow-up, patients on Alecensa demonstrated a 57.0% decline in the risk of disease progression or death compared to patients receiving crizotinib therapy. The success in the clinical trials is expected to help the company’s regulatory filing for label expansion and simultaneously strengthen the commercialization capabilities of Alecensa.
In August, the China National Drug Administration (or CNDA) approved Alecensa monotherapy for the treatment of individuals with anaplastic lymphoma kinase (or ALK) positive advanced non-small cell lung cancer (or NSCLC). The CNDA approval of Alecensa was based on the data from the global pivotal phase 3 ALEX trial.
Some important drugs for NSCLC from Roche’s peers include Pfizer’s (PFE) Xalkori and Boehringer Ingelheim’s Gilotrif. Pfizer’s Xalkori reported revenues of $290.0 million in the second quarter.